ANGIOGENIC AND INFLAMMATORY MARKERS IN THE INTRAOCULAR FLUID OF EYES WITH DIABETIC MACULAR EDEMA AND INFLUENCE OF THERAPY WITH BEVACIZUMAB

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Retina

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/IAE.0b013e3181e095c0PMID 20711086
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of vitreous inflammatory factors with diabetic macular edema.

  2009cited by this paper
• Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.

  2009cited by this paper
• Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

  2009cited by this paper
• Diabetic complications and dysregulated innate immunity.

  2008cited by this paper
• Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

  2008cited by this paper
• Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion

  2008cited by this paper
• Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients

  2008cited by this paper
• Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.

  2007cited by this paper
• Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy.

  2007cited by this paper
• Independent effects of complement factor H Y402H polymorphism and cigarette smoking on risk of age-related macular degeneration.

  2007cited by this paper
• A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

  2007cited by this paper
• Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Exudative Age-Related Macular Degeneration and Diffuse Diabetic Macular Edema

  2007cited by this paper
• ROLE OF MACROPHAGES IN COMPLICATIONS OF TYPE 2 DIABETES

  2007cited by this paper
• Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.

  2007influential reference
• Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA

  2006influential reference
• Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.

  2005cited by this paper
• Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A.

  2005cited by this paper
• Interleukin‐8, monocyte chemoattractant protein‐1 and IL‐10 in the vitreous fluid of patients with proliferative diabetic retinopathy

  2005cited by this paper
• Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients

  2004cited by this paper
• A central role for inflammation in the pathogenesis of diabetic retinopathy

  2004cited by this paper
• The Role of Human Mast Cell-Derived Cytokines in Eosinophil Biology

  2004cited by this paper
• The role of growth factors in the pathogenesis of diabetic retinopathy

  2004cited by this paper
• Vascular endothelial growth factors and angiogenesis in eye disease.

  2003cited by this paper
• Relation of diabetic macular edema to cytokines and posterior vitreous detachment.

  2003cited by this paper
• Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives

  2003cited by this paper
• Molecular understanding of hyperglycemia's adverse effects for diabetic complications.

  2002cited by this paper
• Diabetic retinopathyA clinical update.

  2002cited by this paper
• Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy.

  2002cited by this paper
• Diabetic retinopathy

  2002cited by this paper
• Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.

  2002cited by this paper
• [Diabetic retinopathy].

  2001influential reference
• VEGF-initiated blood-retinal barrier breakdown in early diabetes.

  2001cited by this paper
• Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study.

  1999cited by this paper
• Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid.

  1998cited by this paper
• Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy.

  1997cited by this paper
• Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease.

  1997cited by this paper
• During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium

  1996cited by this paper
• During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium.

  1996cited by this paper
• Localization of vascular endothelial growth factor in human retina and choroid.

  1996cited by this paper
• The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities

  1996cited by this paper
• Hypoxic regulation of vascular endothelial growth factor in retinal cells.

  1995influential reference
• The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema.

  1995cited by this paper
• Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group.

  1991cited by this paper
• Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group.

  1987cited by this paper
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

  1985cited by this paper

• Classification of Diabetic Retinopathy Severity with Aqueous VEGF Levels: A Prospective, Observational Study

  2025cites this paper
• Liquid Biopsy Combined with Multi-Omics Approaches in Diagnosis, Management, and Progression of Diabetic Retinopathy

  2025cites this paper
• Analysis of 24 pro-inflammatory cytokines in aqueous and serum of 94 patients without diabetes

  2025cites this paper
• Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?

  2024cites this paper
• Resolution of diabetic macular edema following silicone oil removal

  2024cites this paper
• Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review

  2024cites this paper
• Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema

  2024cites this paper
• Comparison of the cytokines levels in aqueous humor in vitrectomized eyes versus non-vitrectomized eyes with diabetic macular edema

  2024cites this paper
• Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells

  2024cites this paper
• Effect of dexamethasone implant on intraocular cytokines in diabetic macular edema

  2023cites this paper
• Diabetic Macular Edema - Diagnostics and Treatment Guidelines.

  2023cites this paper
• Study of aqueous humour inflammatory mediators’ levels in a cohort of Egyptian patients with diabetic macular oedema

  2023cites this paper
• Monoclonal antibodies in diabetic retinopathy

  2022cites this paper
• Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study

  2022cites this paper
• The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers

  2022cites this paper
• Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta‐analysis

  2021cites this paper
• Intravitreal bevacizumab versus intravitreal triamcinolone for diabetic macular edema–Systematic review, meta-analysis and meta-regression

  2021cites this paper
• Comparison of Inflammatory and Angiogenic Factors in the Aqueous Humor of Vitrectomized and Non-Vitrectomized Eyes in Diabetic Macular Edema Patients

  2021cites this paper
• Changes of retinal oxygen saturation during treatment of diabetic macular edema with a pre-defined regimen of aflibercept: a prospective study

  2021cites this paper
• IL-17A Damages the Blood–Retinal Barrier through Activating the Janus Kinase 1 Pathway

  2021cites this paper
• Intraocular fluid biomarkers (liquid biopsy) in human diabetic retinopathy

  2021cites this paper
• AI-based monitoring of retinal fluid in disease activity and under therapy.

  2021cites this paper
• Melatonin prevents blood-retinal barrier breakdown and mitochondrial dysfunction in high glucose and hypoxia-induced in vitro diabetic macular edema model.

  2021cites this paper
• Claudin-5 Redistribution Induced by Inflammation Leads to Anti-VEGF–Resistant Diabetic Macular Edema

  2020cites this paper
• Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group

  2020cites this paper
• The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis

  2020cites this paper
• Innate immune response in retinal homeostasis and inflammatory disorders.

  2020cites this paper
• Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy

  2020cites this paper
• Ocular Pharmacokinetics and Drug Delivery Challenges

  2020cites this paper
• Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema

  2020cites this paper
• Circular RNA COL1A2 promotes angiogenesis via regulating miR-29b/VEGF axis in diabetic retinopathy.

  2020cites this paper
• Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Steroid for Treatment-Naive Diabetic Macular Edema in a Real-Life Setting

  2020cites this paper
• Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group

  2020cites this paper
• COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.

  2020cites this paper
• Correlation between anterior chamber flare changes and diabetic macular edema after intravitreal injection of ranibizumab and aflibercept

  2020cites this paper
• Cytokines and Growth Factors as Predictors of Response to Medical Treatment in Diabetic Macular Edema

  2020influential citation
• Einfluss der Selektiven Retinatherapie (SRT) auf inflammatorische Zellmediatoren des subretinalen Raums

  2019cites this paper
• Evidence-Based Guidelines for Management of Diabetic Macular Edema

  2019cites this paper
• Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.

  2019cites this paper
• DDDT_A_222004 4367..4374

  2019cites this paper
• Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema

  2019cites this paper
• Aqueous Humor Mediator and Cytokine Aberrations in Diabetic Retinopathy and Diabetic Macular Edema: A Systematic Review and Meta-Analysis

  2019cites this paper
• Serum pro‐inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti‐VEGF: association with intravitreal injection treatment profiles in real‐world setting

  2019cites this paper
• Patterns of morphologic alteration correlate with vision in diabetic macular oedema: a cross‐sectional evaluation of patients using the SAVE II protocol

  2019cites this paper
• Changes in VEGF-related factors are associated with presence of inflammatory factors in carbohydrate metabolism disorders during pregnancy

  2019cites this paper
• The effect of single dose adjunctive dexamethasone implant on diabetic macular edema in patients on anti-vascular endothelial growth factor treatment: 1 year follow-up from a real-life practice.

  2019cites this paper
• Association of Plasma Pentraxin-3 Levels with Retinopathy and Systemic Factors in Diabetic Patients

  2018cites this paper
• Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF.

  2018cites this paper
• Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy

  2018cites this paper
• Retina The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema

  2018influential citation
• Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline

  2018cites this paper
• A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema.

  2018cites this paper
• The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema.

  2018cites this paper
• A CCR 2 / 5 Inhibitor , PF-04634817 , Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

  2018cites this paper
• Pathophysiology of diabetic macular edema – a background for current treatment modalities

  2018cites this paper
• Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography

  2017cites this paper
• Biomarcadores no edema macular diabético

  2017cites this paper
• Evolving Role of Regional Depot Corticosteroids in Management of Diabetic Macular Edema

  2017cites this paper
• Müller cells and diabetic retinopathy

  2017cites this paper
• Current and Emerging Treatment for Diabetic Macular Edema

  2017cites this paper
• Effect of preoperative topical diclofenac on intraocular interleukin-12 concentration and macular edema after cataract surgery in patients with diabetic retinopathy: a randomized controlled trial

  2017cites this paper
• Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in ARPE-19 cells.

  2017cites this paper
• Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema

  2017cites this paper
• Imaging retinal inflammatory biomarkers after intravitreal steroid and anti‐VEGF treatment in diabetic macular oedema

  2017cites this paper
• Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial.

  2016cites this paper
• The effect of triamcinolone acetonide or bevacizumab on the levels of proinflammatory cytokines after retinal laser photocoagulation in pigmented rabbits.

  2016cites this paper
• Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy

  2016cites this paper
• The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-κB Axis during Retinal Inflammation

  2016cites this paper
• Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro.

  2016cites this paper
• Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group

  2016cites this paper
• Diabetic macular oedema: pathophysiology, management challenges and treatment resistance

  2016cites this paper
• Pathophysiology and pharmacological targets of VEGF in diabetic macular edema.

  2016cites this paper
• IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration.

  2016cites this paper
• Comparison of Ranibizumab 0.5 mg Versus 1.0 mg for the Treatment of Patients With Clinically Significant Diabetic Macular Edema: A Randomized, Clinical Trial.

  2016cites this paper
• Comparison of aqueous concentrations of angiogenic and inflammatory cytokines based on optical coherence tomography patterns of diabetic macular edema

  2015cites this paper
• Lipid Mediators Are Critical in Resolving Inflammation: A Review of the Emerging Roles of Eicosanoids in Diabetes Mellitus

  2015cites this paper
• A review of therapies for diabetic macular oedema and rationale for combination therapy

  2015cites this paper
• Pathophysiology of Macular Edema in Diabetes, Retinal Vein Occlusion, and Uveitis: A Disease-Related Approach

  2015cites this paper
• Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema

  2015cites this paper
• Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema

  2015cites this paper
• Recent Innovations in Medical and Surgical Retina

  2015cites this paper
• Aqueous Cytokines as Predictors of Macular Edema in Patients with Diabetes following Uncomplicated Phacoemulsification Cataract Surgery

  2015cites this paper
• COMPARISON OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS INTRAVITREAL BEVACIZUMAB AS THE PRIMARY TREATMENT OF CLINICALLY SIGNIFICANT MACULAR EDEMA

  2015influential citation
• Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema.

  2015cites this paper
• Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF

  2014cites this paper
• Aqueous Interleukin-6 (IL-6) Level Is a Marker for Treatment Resistance to Bevacizumab in Age-Related Macular Degeneration —Aqueous Cytokines after Bevacizumab

  2014cites this paper
• Cytokine levels of the aqueous humour in central serous chorioretinopathy

  2014cites this paper
• Different Concentrations of Aqueous Cytokines According to Diabetic Macular Edema Patterns as Determined Optical Coherence Tomography

  2014cites this paper
• Pathophysiology and pharmacological targets of diabetic macular edema : an 1 updated review

  2014cites this paper
• Extracellular Matrix Modulates Angiogenesis in Physiological and Pathological Conditions

  2014cites this paper
• Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy.

  2014cites this paper
• EFFECT OF INTRAVITREAL TRIAMCINOLONE IN DIABETIC MACULAR EDEMA UNRESPONSIVE TO INTRAVITREAL BEVACIZUMAB

  2014cites this paper
• RETINAL MORPHOLOGIC CHANGES AND CONCENTRATIONS OF CYTOKINES IN EYES WITH DIABETIC MACULAR EDEMA

  2014cites this paper
• IL-1β Upregulates IL-8 Production in Human Müller Cells Through Activation of the p38 MAPK and ERK1/2 Signaling Pathways

  2014cites this paper
• Chemokine Mediated Monocyte Trafficking into the Retina: Role of Inflammation in Alteration of the Blood-Retinal Barrier in Diabetic Retinopathy

  2014cites this paper
• Anti-VEGF Therapy for Diabetic Macular Edema

  2014cites this paper
• Aqueous Interleukin-6 Levels Are Superior to Vascular Endothelial Growth Factor in Predicting Therapeutic Response to Bevacizumab in Age-Related Macular Degeneration

  2014cites this paper
• A centrifugal fluidic immunoassay for ocular diagnostics with an enzymatically hydrolyzed fluorogenic substrate.

  2014cites this paper
• Current and future management of diabetic retinopathy : a personalized evidence-based approach Review

  2013cites this paper
• Current and new concepts in the diagnosis and management of diabetic macular oedema

  2013cites this paper